Stephane Angers

STEPHANE ANGERS

GOOGLE SCHOLAR PROFILE

ACADEMIC DEGREES AND APPOINTMENTS:

July 2017-       Professor
Leslie Dan Faculty of Pharmacy
Department of Pharmaceutical Sciences
Department of Biochemistry
University of Toronto

July 2015-       Associate Dean of Research
Leslie Dan Faculty of Pharmacy

2012-2017       Associate Professor
Leslie Dan Faculty of Pharmacy
Department of Pharmaceutical Sciences
Department of Biochemistry
University of Toronto

April 2007-     Canada Research Chair
Functional Architecture of Signal Transduction

2006-2012       Assistant Professor
Leslie Dan Faculty of Pharmacy
Department of Pharmaceutical Sciences
Department of Biochemistry
University of Toronto

2002-2006      Post-doctoral Fellow
Howard Hughes Medical Institute
University of Washington, Seattle
Supervisor: Dr. Randall T. Moon

1998-2002      Ph.D,  Biochemistry,
Université de Montréal, Montréal, Qc
Thesis supervisor: Dr. Michel Bouvier

1993- 1997      B. Sc. Biochemistry
McGill University, Montréal, Qc

Dr. Angers is an expert in the field of signal transduction. He obtained his Ph.D from the Université de Montréal in 2002 under the guidance of Dr. Michel Bouvier. His thesis work led to the development and application of light energy transfer methodology for the study of protein-protein interaction and signal transduction. From 2002-2006 he was a Howard Hughes Post-Doctoral Fellow at the University of Washington in Seattle under the supervision of Dr. Randall T. Moon, where he identified and characterized novel components of the Wnt signalling pathway and a new class of E3 ubiquitin ligases.

In October 2006, Dr. Angers established his independent research program in the Department of Pharmaceutical Sciences at the Faculty of Pharmacy and in the Department of Biochemistry at the University of Toronto. He is the recipient of the Canada Research Chair in Functional Architecture of Signal Transduction. His research program is developed to understand the signalling mechanisms underlying the Wnt and Hedgehog families of growth factors and their signalling mechanisms in development, adult tissue homeostasis and in human diseases. His pioneer work led to the development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers and regenerative medicine applications. He is the scientific founder of two biotech companies, ModMab Therapeutics and AntlerA Therapeutics, which are pursuing the clinical development of these molecules.